CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| A071601 | Alliance | Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas | Adult CIRB - Late Phase Emphasis | Available to Open |
| CALGB-30801 | CALGB | A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| NRG-BR009 | NRG | A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1800A | SWOG | A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) | Adult CIRB - Late Phase Emphasis | Available to Open |
| RTOG-1112 | RTOG | Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1207 | SWOG | Phase III Randomized; Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study - evaluating everolimus with endocrine therapy | Adult CIRB - Late Phase Emphasis | Available to Open |
| A091401 | Alliance | Randomized Phase II Study Of Nivolumab With Or Without Ipilimumab In Patients With Metastatic Or Unresectable Sarcoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| CCTG MA.39 | NCIC CTG | Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA3211 | ECOG-ACRIN | Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1701 | SWOG | A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |